| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
APG-1387 (SM-1387) is a novel and potent IAP inhibitoris with anticancer effects, acting by promoting the rapid degradation of cIAP1/2 and XIAP, enhancing the chemosensitivity and promoting apoptosis in combination with CDDP and 5-FU of NPC in vitro and vivo.
| ln Vitro |
In HepG2 and HCCLM3 cells, dasminapant (0.02–20 μM; 24 hours) causes fast cIAP degradation [1]. In HepG2 and HCCLM3 cells, dasminapant (2 μM; 24 hours) increases TNF-α and TRAIL-mediated anticancer activity. HepG2 and HCCLM3 cells are made more susceptible to NK cell-mediated death in vitro by dasminapant [1].
|
|---|---|
| ln Vivo |
Dasminapant (20 mg/kg; intraperitoneally every 3 days for 4 weeks) sensitizes HCCLM3 tumors to NK cell-mediated killing in mice [1]. Dasminapant (20 mg/kg; intraperitoneally every 3 days for 4 weeks) monotherapy showed modest antitumor effects and was well tolerated in mice [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HepG2 and HCCLM3 Cell Tested Concentrations: 0.02, 0.2, 2, 20 μM Incubation Duration: 1, 6, 24 hrs (hours) Experimental Results: At a certain dose and dosage, the expression of cIAP1 and cIAP2 in both cell lines Expressions are all diminished in a time-dependent manner. Inhibits the expression of X chromosome-linked IAP (XIAP) at high doses. |
| Animal Protocol |
Animal/Disease Models: Non-obese diabetic and severe combined immunodeficiency (NOD-SCID) mice bearing HCCLM3 tumors were injected with NK cells [1]
Doses: 20 mg/kg Route of Administration: intraperitoneally (ip) (ip) every 3 days for 4 weeks Experimental Results: cIAP1 expression was diminished and cIAP2 had a weak effect on XIAP expression. Enhanced effects of preactivated NK cells on HCCLM3 xenograft tumor growth and tumor weight. |
| References |
|
| Additional Infomation |
APG-1387 is under investigation in clinical trial NCT04568265 (A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B).
Dasminapant is a small molecule, second mitochondria-derived activator of caspases (SMAC)-mimetic targeting inhibitor of apoptosis proteins (IAPs) with potential apoptosis-inducing and antineoplastic activities. Upon administration, dasminapant selectively binds to and inhibits the activity of IAPs including X chromosome-linked IAP (XIAP) and cellular IAPs 1 (c-IAP1) and 2 (c-IAP2). This may restore and promote the induction of apoptosis through apoptotic signaling pathways and enhance proteasomal degradation of IAPs. Additionally, dasminapant may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains. |
| Molecular Formula |
C60H72N10O10S2
|
|---|---|
| Molecular Weight |
1157.4047
|
| Exact Mass |
1156.487
|
| CAS # |
1570231-89-8
|
| PubChem CID |
73336238
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.681
|
| LogP |
4.09
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
82
|
| Complexity |
2240
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
S(C1C([H])=C([H])C([H])=C(C=1[H])S(N1C([H])([H])[C@@]([H])(C(N2[C@]([H])(C(N([H])C([H])(C3C([H])=C([H])C([H])=C([H])C=3[H])C3C([H])=C([H])C([H])=C([H])C=3[H])=O)C([H])([H])C([H])([H])[C@]2([H])C([H])([H])C1([H])[H])=O)N([H])C([C@]([H])(C([H])([H])[H])N([H])C([H])([H])[H])=O)(=O)=O)(N1C([H])([H])[C@@]([H])(C(N2[C@]([H])(C(N([H])C([H])(C3C([H])=C([H])C([H])=C([H])C=3[H])C3C([H])=C([H])C([H])=C([H])C=3[H])=O)C([H])([H])C([H])([H])[C@]2([H])C([H])([H])C1([H])[H])=O)N([H])C([C@]([H])(C([H])([H])[H])N([H])C([H])([H])[H])=O)(=O)=O
|
| InChi Key |
AKLBERUGKZNEJY-RTEPGWBGSA-N
|
| InChi Code |
InChI=1S/C60H72N10O10S2/c1-39(61-3)55(71)63-49-37-67(34-32-45-28-30-51(69(45)59(49)75)57(73)65-53(41-18-9-5-10-19-41)42-20-11-6-12-21-42)81(77,78)47-26-17-27-48(36-47)82(79,80)68-35-33-46-29-31-52(70(46)60(76)50(38-68)64-56(72)40(2)62-4)58(74)66-54(43-22-13-7-14-23-43)44-24-15-8-16-25-44/h5-27,36,39-40,45-46,49-54,61-62H,28-35,37-38H2,1-4H3,(H,63,71)(H,64,72)(H,65,73)(H,66,74)/t39-,40-,45+,46+,49-,50-,51-,52-/m0/s1
|
| Chemical Name |
(5S,8S,10aR)-3-[3-[[(5S,8S,10aR)-8-(benzhydrylcarbamoyl)-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-3-yl]sulfonyl]phenyl]sulfonyl-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~43.20 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (2.16 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8640 mL | 4.3200 mL | 8.6400 mL | |
| 5 mM | 0.1728 mL | 0.8640 mL | 1.7280 mL | |
| 10 mM | 0.0864 mL | 0.4320 mL | 0.8640 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
